Implementing VTE Prevention in Ambulatory Cancer Care | NCT07292376

Studies
Implementing VTE Prevention in Ambulatory Cancer Care

NCT07292376

Sponsor

University of Vermont

Status

Enrolling by invitation

Last Update Posted

Dec 18, 2025Actual

Enrollment

25Estimated

Phase

Not Applicable

Conditions

Venous Thromboembolism
Neoplasms

Interventions

Clinical program

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Dec 2025

Overall Recruitment Status or Expanded Access Status

Enrolling by invitation

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Oct 1, 2025Actual

Primary Completion Date

Apr 30, 2026Estimated

Completion Date

Jul 30, 2026Estimated

First Submitted Date

Dec 5, 2025

First Submission Date that Met QC Criteria

Dec 5, 2025

First Posted Date

Dec 18, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Dec 5, 2025

Last Update Posted Date

Dec 18, 2025Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

assess effectiveness of a , compared with usual care, to assess

The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in ambulatory patients with cancer. The main question[s] it aims to answer are:

Does the modified program improve number of ambulatory oncology patients starting systemic treatment getting VTE risk-assessment? Does the modified program improve the number of patients receiving appropriate preventative anticoagulation? Researchers will compare to usual care (no clinical program).

Participant clinicians will be asked to

receive education about VTE prevention recommendations
carry out risk assessment, anticoagulation discussions, and document the results Participant patients will receive care from clinicians participating in the study as part of their cancer care.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

25Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Clinical program	Other		Other: Clinical program

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Clinical program	Other	Revised Vermont Model clinical program, including standardized education and training for oncology care team, clinical decision support and revised workflow for VTE risk assessment and thromboprophylaxis.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Documented VTE risk assessment	Proportion of new patients who have documented VTE risk assessment	30 days after new patient appointment

Secondary Outcomes

Measure	Description	Time Frame
Appropriate thromboprophylaxis	Proportion of identified high-risk patients with prescription for thromboprophylaxis and low-risk patients without thromboprophylaxis	30 days after new patient appointment

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Clinicians: practicing oncologist at study clinic site (UVMMC)
Patients: diagnosis of cancer; starting new systemic cancer-directed therapy at a study clinic site under the direction of the enrolled clinician

Exclusion Criteria:

none

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Karlyn Martin, MD	University of Vermont	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Vermont Health		Burlington	Vermont	05405	United States

IPD Sharing Statement Module

Plan to Share IPD

Description

Not provided

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided

Condition Browse Module

MeSH Terms

ID	Term
D054556	Venous Thromboembolism
D009369	Neoplasms

Ancestor Terms

ID	Term
D013923	Thromboembolism
D016769	Embolism and Thrombosis
D014652	Vascular Diseases
D002318	Cardiovascular Diseases

Browse Leaves

Not provided

Browse Branches

Not provided